
TMDX Stock Forecast & Price Target
TMDX Analyst Ratings
Bulls say
TransMedics Group Inc. has demonstrated significant operating margin expansion, with expectations of over 16% improvement and an increase of at least 750 basis points, indicating strong financial performance. The company’s momentum is supported by promising tailwinds, including the adoption of its Organ Care System (OCS) and anticipated growth in organ transplant volumes, which are projected to rise approximately 35.2% year-over-year in Q4. Additionally, the company is poised for robust revenue growth, with estimated U.S. sales reaching $163.9 million, reflecting a 40.5% increase year-over-year, surpassing previous consensus estimates.
Bears say
TransMedics Group Inc. has experienced a concerning decline in key operational metrics, such as a decrease in daily flights and flight hours, which have fallen to levels similar to those recorded in the first quarter of 2025. Despite reporting an increase in product revenues of 33.1% year-over-year, the company fell approximately $1 million short of consensus expectations, which may negatively impact its stock performance. Furthermore, the company's reliance on successful product introductions and its struggles to expand and scale its salesforce present significant commercialization risks, exacerbated by competitive pressures and potential regulatory challenges.
This aggregate rating is based on analysts' research of Transmedics Group Inc and is not a guaranteed prediction by Public.com or investment advice.
TMDX Analyst Forecast & Price Prediction
Start investing in TMDX
Order type
Buy in
Order amount
Est. shares
0 shares